DIRS.INFO The most relevant business & tech news

➡️ In a CNN town hall, Harris called Trump a “fascist” and said he suggested he is unfit for office. Earlier in the day, she blasted Trump’s reported praise of Hitler. ➡️ The Harris campaign says it’s preparing for a deluge of litigation before and after Election Day. ➡️ Seven maps show how Trump, Harris and their running mates are dividing their time in critical swing states. ➡️ Trump’s reported racist insult about a slain Mexican American soldier has drawn backlash and staunch denials.

Persons: Donald Trump isn’t, McDonald’s, Trump, Harris, Donald Trump, Kamala Harris, they’ve, ”, Tim Walz, ➡️ Harris, Trump’s, Hitler, ➡️, Hillary Clinton, Elon Musk’s, ➡️ Trump’s, ➡️ Trump, Boeing machinists, machinists, Helene, Peter O’Leary, O’Leary, Robert Card, George Frey, Gaza Mahmoud Issa, Chantal Da Silva, Elizabeth Robinson Organizations: Boeing, NBC, Israel, CNN, Steelers, Trump, State, DOJ, GOP, CDC, NBC News, FEMA, Semaglutide, PBS, Anadolu, Getty, United Nations, NBC News ’, Atlas Coffee Locations: Traverse City , Michigan, Detroit, New York, Pittsburgh, Mexican, Colorado, Here’s, U.S, North Carolina, Chimney Rock , North Carolina, Pennsylvania, Lewiston , Maine, Wyoming, Jackson , Wyoming, Georgia, Gaza

☆ Eli Lilly's blowout quarter should quiet investor concerns about the stock
▼ + stars: | 2024-08-08 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. The report left little doubt that Eli Lilly's best days are ahead, driven by the growth of GLP-1s. It's really early" for Zepbound, Eli Lilly CEO David Ricks said in a CNBC interview Thursday. But the good news is Eli Lilly's multibillion dollar investments to expand manufacturing capacity are paying off.

Persons: Eli Lilly, Eli Lilly's, Zepbound, Jim Cramer, Lilly, David Ricks, It's, We're, Eli Lilly hasn't, Novo, spooked Lilly, Gordon Brooks, it's, Ricks, Brooks, Verzenio, —, didn't, Jim Cramer's, Jim, George Frey Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, CNBC, Food and Drug Administration, Viking Therapeutics, Novo Nordisk —, FDA, RTP, Bloomberg, Getty Locations: Eisai, U.S, GLP, Roche, it's, Indianapolis, North Carolina, Europe, Germany, Provo , Utah

☆ Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

George Frey | ReutersAn older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial released on Tuesday. Novo Nordisk sells liraglutide as a diabetes and obesity drug under the brand names Victoza and Saxenda, respectively. Alzheimer's disease often causes the brain to shrink as the illness progresses because crucial nerve cells break down and stop working properly. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. The ongoing EVOKE is examining semaglutide, the active ingredient in Wegovy and Ozempic, in nearly 2,000 Alzheimer's patients.

Persons: George Frey, Eli Lilly, liraglutide, Brian B, Bettencourt, Heather Snyder, Leqembi, Snyder, Dr, Paul Edison, Edison, Bobby Pugh, Bessie Pugh, Karen Pulfer Focht Organizations: Novo Nordisk Pharmaceutical, Reuters, Novo Nordisk, Imperial College London, Alzheimer's Association International Conference, Toronto Star, Getty, Alzheimer's Association, U.S, CNBC, Alzheimer's, Novo Nordisk's, Ave Locations: Provo , Utah, Danish, Philadelphia, Biogen, Novo, Bartlett , Tennessee, U.S

☆ These 10 U.S. states have America’s best economies in 2024
▼ + stars: | 2024-07-18 | by ( Scott Cohn | ) www.cnbc.com time to read: +13 min

We consider economic growth and job growth. We measure the breadth of each state's economy by looking at how many major corporations are headquartered there. Delaware's economy turned in a lackluster performance in 2023 — the only state economy to shrink last year. Mario Tama | Getty ImagesThe Grand Canyon State's surging chip sector is delivering many dividends, including strong job growth and a healthy housing market. But he noted that construction employment grew at a healthy pace last year, evidence that the state economy still has steam left.

Persons: Dupont De Nemours, Ethan Miller, Kevin C, George Frey, Mark Knold, Knold, Zions, Mario Tama, Katie Hobbs, Allison Joyce, they've, Andrew Berger, Gross, Berger, Nina Dietzel, Lawrence Kessler, Kessler, Brandon Bell, Joe Raedle Organizations: Companies, Business, Delaware, Istock, Getty, Fortune, Census, Commerce Department, Aaa, Direct Investment, Corporate, Gem State, Micron Technology, Lamb Weston Holdings, Silver State, Pew, Major Corporations, Vegas Sands, MGM Resorts, Benz, Cox, Mercedes, Nestlé, Purina, Adidas, Georgia Department of Economic, U.S . Commerce Department, Assurant, Intercontinental, Contractors, Bloomberg, Utah's Department of Workforce Services, Arizona Workers, Gov, Democrat, Major, Technology, North, Health, Employers, North Carolina Department of Commerce, Corporate Headquarters, Bank of America, Duke Energy, Tennessee, University of Tennessee, The Volunteer State, FedEx, Texas Employees, Lone Star State, Entrepreneurship, Oracle, Tesla, Amerant Locations: States, Wilmington, New Castle County , Delaware, Delaware, Incyte, Idaho, Boise , Idaho, USA, Nevada, Las Vegas, Las Vegas , Nevada, Southern California, Vegas, Georgia, Atlanta , Georgia, Peach, Utah, Provo , Utah, U.S, Beehive, Buckeye , Arizona, Arizona, North Carolina, Wilmington , North Carolina, Carolina, Tennessee Nashville , Tennessee, Luling , Texas, The Texas, North Dakota, California, Texas, Florida, Sunrise , Florida

☆ Federal Trade Commission to sue drug middlemen over prices of medications including insulin, source says
▼ + stars: | 2024-07-10 | by ( Annika Kim Constantino Mary Catherine Wellons | Annika Kim Constantino | Mary Catherine Wellons | ) www.cnbc.com time to read: +3 min

Joe Raedle | Getty ImagesAn Express Scripts spokesperson said the "prices of insulin and other medicines are set by their manufacturers, who have raised list prices repeatedly." They also create lists of medications — or formularies — that are covered by insurance and reimburse pharmacies for prescriptions. The investigation into insulin prices also examines drugmakers, but it is unclear whether they will be named in the upcoming lawsuits, Politico reported, citing people familiar with the matter. Eli Lilly , French drugmaker Sanofi and Danish pharmaceutical company Novo Nordisk control roughly 90% of the U.S. insulin market. Pharmacist Thomas Jensen looks over a prescription drug at the Rock Canyon Pharmacy in Provo, Utah, on May 9, 2019.

Persons: Lina Khan, Tom Williams, Joe Raedle, PBMs, Eli Lilly, Sanofi, Thomas Jensen, George Frey Organizations: Trade, Financial Services, General Government, CQ, Inc, Getty, Federal Trade Commission, CNBC, UnitedHealth, CVS, FTC, Politico, Novo Nordisk, Pharmacy Locations: Miami, U.S, Danish, Provo , Utah

Joe Raedle | Getty ImagesAn Express Scripts spokesperson said "the prices of insulin and other medicines are set by their manufacturers, who have raised list prices repeatedly." The FTC's investigation into insulin prices also examines drugmakers, but it is unclear whether they will be named in the upcoming lawsuits, Politico reported, citing sources. Eli Lilly , French drugmaker Sanofi and Danish pharmaceutical company Novo Nordisk control roughly 90% of the U.S. insulin market. They also create lists of medications – or formularies – that are covered by insurance and reimburse pharmacies for prescriptions. Pharmacist Thomas Jensen looks over a prescription drug at the Rock Canyon Pharmacy in Provo, Utah, on May 9, 2019.

Persons: Lina Khan, Tom Williams, Joe Raedle, Eli Lilly, Sanofi, Thomas Jensen, George Frey Organizations: Trade, Financial Services, General Government, CQ, Inc, Getty, Federal Trade Commission, CNBC, UnitedHealth, CVS, Politico, Novo Nordisk, Pharmacy Locations: Miami , Florida, Danish, U.S, Provo , Utah

☆ Patagonia gave 90 staff a choice — relocate across the US or leave the company. They've got 3 days to decide.
▼ + stars: | 2024-06-27 | by ( Polly Thompson | ) www.businessinsider.com time to read: +7 min

CX employees must now live within 60 miles of one of seven "hubs" — Atlanta, Salt Lake City, Reno, Dallas, Austin, Chicago, or Pittsburgh. AdvertisementPatagonia verified the details of the announcement to BI, confirming that 90 of 255 CX staff in the US were affected. Both employees BI spoke to said they were accepting the severance and did not know anyone who was considering relocation. AdvertisementPatagonia spokesperson Corley Kenna told BI several employees had already indicated they would relocate. Advertisement"The reality is that our CX team has been running at 200% to 300% overstaffed for much of this year," Kenna told BI.

Persons: —, Amy Velligan, Bruce Old, George Frey, I've, Corley Kenna, Kenna, We've, Yvon Chouinard, Harris, Chouinard, Jean, Marc Giboux, Yvon Chouinard's, Yvon, it's Organizations: Service, Business, Workers, Walmart, Patagonia, BI, Reno, New York Times, Washington Post Locations: Patagonia, Atlanta, Salt Lake City, Reno, Dallas, Austin, Chicago, Pittsburgh, California, Ventura, Nevada

☆ RV sales are picking up. That’s a good sign for the economy
▼ + stars: | 2024-06-16 | by ( Alicia Wallace | ) edition.cnn.com time to read: +10 min

When consumer sentiment falters or the economy starts to teeter, RV sales follow suit, said Michael Hicks, an economics professor at Ball State University and director of Indiana University’s Center for Business and Economic Research. “People don’t make these large, luxury purchases unless they’re actually feeling better about the economy,” said Hicks, who follows the RV industry closely. “It’s so sensitive to interest rate changes, which often precede a downturn.”A Winnebago travel trailer at Motor Sportsland RV dealership in Salt Lake City on April 6, 2020. Nika Shneyder and her father and business partner, Alex Shneyder, standing by a Chill RV in Malibu RV Park, California, in 2019. They moved down to a historically strong, but noticeably smaller, 493,000 the next year, according to data from the RV Industry Association.

Persons: That’s, Nika Shneyder, “ We’re, ” Shneyder, “, Michael Hicks, ”, Hicks, George Frey, bode, ” Michael J, Happe, hasn’t, We’ve, we’ve, Covid, Alex Shneyder, Nika, they’d, Monika Geraci, David Titus, Ty Wright, there’s, Ball State’s Hicks, ’ Titus, they’re, we’ll, Titus, ” Titus Organizations: CNN, Ball State University, Indiana University’s Center for Business, Economic Research, Bloomberg, Getty, Winnebago Industries, RV Industry, Dealers, RVs, Consumers, HL Enterprise, Manufacturing, of Labor Statistics Locations: Los Angeles, teeter, Salt Lake City, YOLO, Malibu, , California, Elkhart , Indiana, The Northern Indiana, South Bend, Elkhart, “, Elkhart .

One of the architects of that plan for a Trump second term said as much in a video last year for the Heritage Foundation. Reissuing Schedule F is part of a roadmap, known as Project 2025, drafted for a second Trump term by scores of conservative groups and published by the Heritage Foundation. The new rules would not fully block reclassifying workers in a second Trump term. Greene said she worries for federal workers who might face the same choice in a second Trump term. The project includes a personnel database for potential hires in a second Trump administration.

Persons: Donald Trump, it’s, —, Trump, Joe Biden, Donald Moynihan, Georgetown University's, ” Donald Moynihan, ” Moynihan, “ It’s, ”, Russell Vought, “, you’re, Doreen Greenwald, Moynihan, Kenneth Baer, Barack Obama, ” Kenneth Baer, Peter Orszag, Pete Souza, Robert Shea, Eva Shea, George W, Bush, Laura Bush, Tina Hager, ” Biden, Baer, George Frey, ” Trump, Max Stier, Verna Daniels, ” Daniels, Catherine Greene, ” Greene, Tom Bewick, NIFA, ” Bewick, we’ll, Greene, Biden, “ We’ve, He’s, Hillary Clinton, he’d, James Comey, Bill Barr, Barr, Jeffrey Clark, Clark, Mark Meadows, Stephen Miller, Peter Navarro, he’ll Organizations: CNN, United, Republican, Democratic, Trump, ”, Georgetown, Georgetown University's McCourt School, Public, Georgetown University, Heritage Foundation, Management, Budget, of Justice, FBI, Environmental Protection Agency, Vought, National Treasury Employees Union, OMB, White, Personnel Management, Land Management, Department of Agriculture, Kansas City, Partnership for Public Service, Government, Office, GAO, Economic Research Service, National Institute of Food, Agriculture, USDA, National Institute for Food, NIFA, Applied Economics Association, BLM, Getty, Department of Justice, Justice Department, Univision, Justice, Department, U.S . Justice, Center, Washington Post, National Security and Intelligence, of Homeland Security, of Education and Commerce, Federal Communications Commission, Federal Trade Commission Locations: United States, Washington, Georgetown, , Colorado, DC, Kansas, Colorado, Virginia, America, Grand Junction, Washington ,, New York City, New York, Georgia

☆ Eli Lilly's top-selling drug last year is softening. But it may not matter for the stock
▼ + stars: | 2024-04-12 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Sales of some Eli Lilly drugs — including its best-selling product last year — appear to be softening, according to Wall Street analysts. JPMorgan flagged similar trends for Trulicity, which led all Lilly drugs with $7.13 billion in sales for all of 2023. The thesis is predicated on Eli Lilly growing faster than the broader pharmaceutical industry for years to come. Over the past three years, shares of Eli Lilly have soared nearly 300%, compared with a 24% gain for the S & P 500 . A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.

Persons: Eli Lilly, Wells, Lilly, Mounjaro, Jim Cramer, tirzepatide, Zepbound, Eli Lilly's, Novo, Wegovy, drugmaker, Jim Cramer's, Jim, Eli Lilly Pharmaceutical, George Frey Organizations: Wall Street, JPMorgan, Club, Novo Nordisk, Novo, BMO Capital Markets, Drug Administration, FDA, The Club, CNBC Locations: Wells Fargo, Trulicity, Tirzepatide, Danish, Lilly, Provo , Utah

Michael Cargill, owner of Central Texas Gun Works in Austin, opposes the ban on bump stock sales. “During the Trump administration, the bump stock ban cropped up as a rather glaring example of unlawful administrative power,” Philip Hamburger, a founder of the New Civil Liberties Alliance, said in an email. Image A bump stock attaches to a semiautomatic rifle and enables it to fire at a much higher rate. In response, the Justice Department promised to review the legality of bump stocks, but A.T.F. Eventually, the full court agreed with Mr. Cargill by vote of 13 to 3, split along ideological lines.

Persons: Michael Cargill, ”, Cargill, Trump, ” Philip Hamburger, Elizabeth B, Prelogar, George Frey, Cargill strolled, “, Mark Chenoweth, ” Mr, Chenoweth, Obama, ” “, Mr, Charles Koch, Jonathan F, Mitchell, Donald J, Stephen Paddock, Erin Schaff, Jennifer Walker Elrod Organizations: Central Texas Gun, Government, Army, New Civil Liberties Alliance, —, Alcohol, Tobacco, Firearms, Explosives, National Firearms, Charles Koch Foundation, Koch Industries, Colorado Supreme, National Rifle Association, Justice Department, Congress, The New York Times Federal, U.S ., Appeals, Fifth Circuit, Mr, Gun Control Locations: Austin, Las Vegas, ”, “, Texas

☆ Deflation: Here's where prices fell in January 2024, in one chart
▼ + stars: | 2024-02-14 | by ( Greg Iacurci | ) www.cnbc.com time to read: +6 min

These are the big deflationary factors"A lot of factors have come together to push goods prices down," said Mark Zandi, chief economist at Moody's Analytics. In addition to normalizing supply-demand dynamics, a historically strong U.S. dollar relative to other global currencies has also helped rein in goods prices, Zandi said. Falling energy prices have also put downward pressure on goods prices, due to lower transportation and energy-intensive manufacturing costs, economists said. Lower energy prices also put downward pressure on the transportation of food to store shelves. Consumers get more for roughly the same amount of money, which shows up as a price decline in the CPI data.

Persons: RC Willey, George Frey, Jay Bryson, there's, Mark Zandi, Zandi, rebalancing, J.P, Hopper Organizations: RC, Bloomberg, Getty, U.S . Bureau of Labor Statistics, Wells, Wells Fargo Economics, Moody's, U.S . Federal, Services, Finance, Morgan's, Investment, Group, of Labor Statistics Locations: Draper , Utah, Wells Fargo, U.S, Salinas, California

☆ Palo Alto, Eli Lilly and Eaton are up big. Here are entry prices for new investors
▼ + stars: | 2024-02-11 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

Palo Alto Networks , Eli Lilly , and Eaton rallied hard over the past 12 months — up 127%, 117% and 66%, respectively. This $315 level is also close to the 50-day simple moving average (red line). Eli Lilly Two potential entry points: $617 (the 50-day simple moving average) and $541 (the 200-day simple moving average) The 50-day simple moving average is $617, a roughly 16.5% pullback from current levels, while the 200-day simple moving average is $541, a 27% decline. Instead, keep a close eye on that 50-day moving average, looking for that gap between the moving average and the stock price to narrow. As we can see, $242 represents the current 50-day moving average, with $240 representing a level of resistance shares recently surpassed.

Persons: Eli Lilly, Eaton, it's, pullbacks, PANW, Mounjaro, they've, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: Palo Alto Networks, Big Tech, Palo Alto, Jim Cramer's Charitable, CNBC, Bloomberg, Getty Locations: Provo , Utah

☆ Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
▼ + stars: | 2024-02-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

Victoria Klesty | ReutersThe insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly , have said supply woes likely won't go away anytime soon, as the popularity of those medicines continues to soar. Some Wall Street analysts project that the weight loss drug market could be worth $100 billion by the end of the decade. But both Novo Nordisk and Eli Lilly gave updates on positive supply developments to investors over the last week. Other forms of weight loss drugs could helpAlternative forms of weight loss drugs could also help alleviate supply constraints in the future.

Persons: Victoria Klesty, Eli Lilly, Cantor Fitzgerald, Louise Chen, Nordisk's Wegovy, Eli Lilly's Zepbound, Goldman Sachs, Jeff Friedman, Novo, Mike Segar, Eli, Catalent, Yves Herman Yves Herman, TD Cowen, Michael Nedelcovych, Anat Ashkenazi, Cantor Fitzgerald's Chen, Morgan Stanley, Eli Lilly's, George Frey Organizations: Novo Nordisk, CNBC, Nordisk's, University of Florida, Pfizer, AstraZeneca, Roche, Food, Nordisk, Company, FDA, Novo Holdings, Wegovy, REUTERS, Reuters, U.S Locations: Oslo, Norway, Novo, U.S, Branchburg , New Jersey, Brussels, Belgium, Catalent, Concord , North Carolina, North, Germany, Indiana, Denmark, France

☆ We're raising our price target on Eli Lilly by $120 after its excellent quarter
▼ + stars: | 2024-02-06 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +10 min

Bottom line Eli Lilly delivered a strong report Tuesday. Still, it's not a surprise to see shares of Eli Lilly fall nearly 2% Tuesday, to around $694 each. Despite doubling manufacturing capacity year over year in 2023, Eli Lilly said demand for its GLP-1s is "likely to outpace supply" this year. We're raising our Eli Lilly price target to $750 a share from $630, while reiterating our 2 rating on the stock, meaning we'd wait for a pullback before adding to our position. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly's, Lilly's, Eli Lilly, Mounjaro, Zepbound, it's, —, Jim Cramer, Anat Ashkenazi, NASH, Lilly, Jim, Jardiance, Verzenio, Trulicity, donanemab, Ashkenazi, Jim Cramer's, George Frey Organizations: Revenue, LSEG, U.S, Novo Nordisk, Food and Drug Administration, Analysts, Investors, FDA, CNBC, Bloomberg, Getty Locations: Mounjaro's, U.S, Mounjaro, Trulicity, Provo , Utah

☆ 8 more of our stocks report earnings next week. Here's what we want to see
▼ + stars: | 2024-02-03 | by ( Zev Fima | ) www.cnbc.com time to read: +13 min

The three major averages posted gains for the fourth week in row, lifted by strong quarterly earnings results for most of the Big Tech companies and a strong jobs report. A weaker ADP Employment report on Wednesday provided no read-through to the monster January jobs report Friday. Here's what we're keeping an eye on in the coming week: 1. Earnings: It's another big earnings week head for the portfolio, with 8 more of our companies reporting. Consistency is what we appreciate most from nat gas giant Linde , so we're hoping for another quarter of solid earnings growth Tuesday.

Persons: Estee Lauder, Eli Lilly, Mounjaro, Nelson Peltz, Estée Lauder, Tyson, CARR, Jacobs, Willis Towers Watson, Edwards, Walt Disney, Oscar Health, Philip Morris, Armour, BAX, BILL, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: Big Tech, Dow Jones Industrial, Nasdaq, PMI, Apple, Starbucks, Procter, Gamble, GE Healthcare, DuPont, Linde, Ford, General Motors, Trian Partners, Disney, ESPN, Wynn Resorts, Wynn, Vegas, Prix, Estée Lauder Companies, Caterpillar, McDonalds Corp, Allegiant Travel, Bowlero Corp, Tyson Foods, TSN, Air Products & Chemicals, IDEXX Laboratories, CNA Financial Corp, CNA, Timken Company, Graham Corporation, Mesa Laboratories, Sphere Entertainment, Loews Corp, Technologies, Vertex Pharmaceuticals, Semiconductors, Simon Property Group, Amkor Technology, FMC Corporation, FMC, BellRing Brands, Crown Holdings, ChampionX Corporation, Golub Capital BDC, Flexsteel Industries, Kilroy Realty Corp, Gladstone Capital Corp, Unibanco, S.A, Snack Foods Corp, Kimball Electronics, Skyline Corp, Cabot Corporation, Simpson Manufacturing Co, Varonis Systems, Co, GE HealthCare, Linde plc, LIN, Spotify Technology S.A, BP, Hertz Global Holdings, AeroSystems Holdings, Toyota Motor Corp, Cummins, CMI, Software Technologies, AGCO Corporation, Carrier Global Corporation, Lear Corp, CONSOL Energy, Centene Corporation, Gartner, Arcbest Corp, CTS Corporation, Energizer Holdings, Hamilton Lane Incorporated, KKR, Precision Drilling Corporation, Frontier Group Holdings, Waters Corp, Alfa Laval, Aramark Holdings Corp, FirstService Corporation, Garden Sports Corp, New Jersey Resources Corp, nVent Electric plc, PJT Partners, Resources, Sensata Technologies, Ford Motor Company, Enphase Energy, Grill, VF Corp, Edwards Lifesciences Corp, Gilead Sciences, Lumen Technologies, Cognizant Technology Solutions Corp, Weatherford International plc, Amcor plc, Arrowhead Pharmaceuticals, Advanced Energy Industries, Uber Technologies, CVS Health, Roblox Corporation, Ares Capital Corp, Bunge, XPO Logistics, Scotts Miracle, Gro Company, Berry Global, Flex LNG, Equinor ASA, Griffon Corporation, OneMain Holdings, Brookfield Asset Management, Emerson Electric Co, Hilton Worldwide Holdings, Reynolds Consumer Products, Silicon Laboratories, Brands, Sciences, CDW Corp, Fox Corporation, WYNN, PayPal, Arm Holdings plc, ARM, Axcelis Technologies, Mattel, Paycom, Annaly Capital Management, McKesson Corp, Health Corporation, O'Reilly Automotive, Allstate Corp, Fluence Energy, Power Systems, Digital Turbine, Blue Bird Corp, Everest Group, Omega HealthCare, Coty, COTY, ConocoPhillips, Cameco Corp, Philip Morris International, Spirit Airlines, Hershey Company, Lightspeed Commerce, Aurora Cannabis, Lincoln National Corp, P, Tenet Healthcare Corp, Asbury Automotive Group, Arrow Electronics, Baxter International, PetMed, Boyd Gaming Corp, FirstEnergy Corp, Motorola Solutions, Terex Corp, PepsiCo, Growth, AMC Networks, Owl, American Pipeline, TELUS International, Magna International, Newell Brands, Jim Cramer's Charitable, CNBC, Bloomberg, Getty Locations: U.S, China, Macau, Wynn Macau, Valvoline, VVV, ALFVY, Madison, New Jersey, Gilead, Ceridian, ORLY, Paycor, Aurora, Provo , Utah

☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
▼ + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.

Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC

☆ How Eli Lilly plans to fix the supply snag for its blockbuster diabetes drug
▼ + stars: | 2024-01-26 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

They're also at the heart of our investment thesis in Eli Lilly, a longtime Club holding. Shares of Eli Lilly have soared nearly 80% over the past 12 months, including a more-than-5% gain in January alone. In November, Eli Lilly indicated it was on track to meet the goal, which also was made possible by upgrades to existing facilities. Eli Lilly has used KwikPen technology for other diabetes treatments, such as insulin injections, for many years. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly, —, Eli Lilly's, They're, FactSet, Lilly's, Dave Ricks, Ricks, Lilly, there's, Morgan Stanley, Eli, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: CNBC, FDA, Novo Nordisk, JPMorgan Healthcare Conference, Research, Barclays, RTP, —, U.S, JPMorgan, Bloomberg, Getty Locations: Danish, Indianapolis, North Carolina, Carolina, Concord , North Carolina, Germany, U.S, Australia, Canada, KwikPen, Provo , Utah

At issue is whether U.S. bankruptcy law allows Purdue's restructuring to include legal protections for the members of the Sackler family, who have not filed for personal bankruptcy. Members of the Sackler family have denied wrongdoing but expressed regret that OxyContin "unexpectedly became part of an opioid crisis." They said in May that the bankruptcy settlement would provide "substantial resources for people and communities in need." The administration told the Supreme Court that Purdue's settlement is an abuse of bankruptcy protections meant for debtors in "financial distress," not people like the Sacklers. The administration has also alleged that the Sackler family members withdrew $11 billion from Purdue before agreeing to contribute $6 billion to its opioid settlement.

Persons: painkiller, George Frey, Joe Biden's, Sackler, Biden, OxyContin, John Kruzel, Andrew Chung, Will Dunham Organizations: Purdue Pharma L.D, REUTERS, Rights, Purdue Pharma, WASHINGTON, U.S, Supreme, Purdue, Circuit, Thomson Locations: Provo , Utah, U.S, Stamford , Connecticut, Manhattan

☆ US Supreme Court to scrutinize controversial opioid crisis settlement that would give Sackler family immunity
▼ + stars: | 2023-12-04 | by ( Samantha Delouya | ) edition.cnn.com time to read: +7 min

Barring individual victims from pursuing their own lawsuits against the Sackler family “raises serious constitutional questions,” the department argued. OxyContin’s commercial success helped the Sackler family earn billions of dollars and the family became known for philanthropy around the world. As the country’s opioid crisis worsened, attention shifted to the role played by Purdue Pharma and the Sackler family. Many of the suits allege that the Sackler family knew of OxyContin’s addictive properties but, nevertheless, continued to promote the drug. The Supreme Court hearing comes at a time of devastating losses due to drug overdoses in the US.

Persons: Los Angeles CNN —, Sackler, Mortimer, Raymond Sackler, “, George Frey, Elizabeth Prelogar, ” Anthony Casey, , –, Purdue Frederick, ” Lindsey Simon, ” Organizations: Los Angeles CNN, Purdue, New, US, US Justice Department, Purdue Pharma, Supreme, Knoa Pharma, Purdue Pharma L.P, Bloomberg, Sackler, ”, University of Chicago, school’s, Law, Finance, Guggenheim, Centers for Disease Control, “, Emory University Locations: New York, Purdue, Provo , Utah, U.S, United States, Paris

REUTERS/George Fre/File Photo Acquire Licensing RightsNov 27 (Reuters) - Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly's (LLY.N) Mounjaro than those taking Novo Nordisk's (NOVOb.CO) popular rival weight loss drug, according to an analysis of health records and other data. After 3 months of treatment, patients on Mounjaro had lost an average of 2.3% more body weight than those taking Ozempic, the study also found. By 6 months, the difference had widened to 4.3%, and by 12 months, the Mounjaro group had lost an average of 7.2% more weight. An Eli Lilly spokesperson said the company does not promote or encourage the off-label use of any of its medicines, although its drug is now approved for weight loss. A trial is underway comparing the weight loss formulations of the two injected medicines in patients overweight or obese but without type 2 diabetes.

Persons: Lilly, George Fre, Eli Lilly's, Mounjaro, Eli Lilly, Nancy Lapid, Bill Berkrot Organizations: Novo Nordisk, Pharmacy, REUTERS, Novo, Thomson Locations: Provo , Utah, U.S

REUTERS/George Frey/File Photo Acquire Licensing RightsNov 21 (Reuters) - Tema ETFs has launched a new exchange traded fund (ETF) that tracks popular drugmakers like Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N), aiming to tap into growing demand for their weight-loss and diabetes drugs. The Tema Cardiovascular & Metabolic ETF (HRTS.O) invests in companies tackling diabetes, obesity and cardiovascular diseases, according to the New York-headquartered platform's website. The advances of the class of weight-loss and diabetes therapies known as GLP-1 receptor agonists, are only the tip of the iceberg, said David K. Song, investment partner and head of life sciences at Tema ETFs. The Tema fund has a net expense ratio of 0.75%. Reporting by Bansari Mayur Kamdar in Bengaluru; Editing by Emelia Sithole-MatariseOur Standards: The Thomson Reuters Trust Principles.

Persons: Lilly, George Frey, Eli Lilly, Mounjaro, David K, Morgan Stanley, Bansari Mayur, Emelia Sithole Organizations: Novo Nordisk, Pharmacy, REUTERS, Metabolic, Morgan Stanley Research, VanEck Pharmaceutical, Thomson Locations: Provo , Utah, U.S, Tema, Novo, New York, Bengaluru

Analysts attended earnings calls in the third quarter armed with questions for healthcare and consumer companies about the potential effect on their sales from the growing popularity of these drugs, known as GLP-1 agonists. A Reuters analysis of earnings transcripts for the third quarter showed "GLP-1" or alternatives like "obesity" or "weight-loss medications" were mentioned 256 times across 29 U.S. and European healthcare and consumer companies. That's more than double the mentions for the second quarter, when those phrases came up 127 times. While some consumer companies have talked about factors such as fewer calories being consumed, "these kind of large extrapolations" seem to be a bit of a stretch, said BMO Capital analyst Evan Seigerman. For big pharma manufacturers like Pfizer (PFE.N) and Amgen (AMGN.O), analyst questions were aimed at their obesity drug candidates.

Persons: Lilly, George Frey, Jeff Jonas, it's, Eli Lilly's, John Furner, Mondelez, Eli Lilly, Evan Seigerman, LVMH, Rajesh Kumar, Jonas, Bhanvi Satija, Savyata Mishra, Arpan Varghese, David Gaffen, Shounak Organizations: Novo Nordisk, Pharmacy, REUTERS, Gabelli, Novo, Walmart, Walmart U.S, Hershey, Truist Securities, Krispy, BMO Capital, Danish, pharma, Pfizer, Devices, HSBC, Thomson Locations: Provo , Utah, U.S, United States, Novo, Bengaluru

☆ German drug regulator considering export ban on Ozempic
▼ + stars: | 2023-11-15 | by ( ) www.reuters.com time to read: +1 min

[1/2] A box of Ozempic, a semaglutide injection drug used for treating type 2 diabetes and made by Novo Nordisk, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey REFILE - CORRECTING MONTH/File Photo Acquire Licensing RightsCompanies Novo Nordisk A/S FollowBERLIN, Nov 15 (Reuters) - The head of Germany's drug regulator BfArM is considering an export ban on Novo Nordisk's (NOVOb.CO) diabetes drug Ozempic, which is in high demand for its weight-loss benefits, to prevent a further worsening of a supply shortage. There is a risk of Ozempic being moved out of the country because it is cheaper there than in many other countries, BfArM president Karl Broich told Spiegel magazine. "We know that some of the syringes that are supplied to Germany for our diabetes patients are channelled to other European countries or the United States," he told Spiegel on Wednesday. We need the medication for the care of diabetes patients and not as a lifestyle drug."

Persons: George Frey REFILE, Karl Broich, Spiegel, Miranda Murray, Ludwig Burger Organizations: Novo Nordisk, Pharmacy, REUTERS, Novo Nordisk's, Spiegel, Ludwig Burger Our, Thomson Locations: Provo , Utah, U.S, Germany, United States

☆ German regulator eyes Ozempic export ban amid shortages across Europe
▼ + stars: | 2023-11-15 | by ( Ludwig Burger | ) www.reuters.com time to read: +5 min

Use of Ozempic for weight loss has caused shortages across Europe. Novo Nordisk, which has earmarked $6 billion to boost production in Denmark, said last week the industry was far from being able to produce enough weight-loss drugs to meet global demand. The German association of drug wholesale distributors PHAGRO said in a statement that there was no certainty that exports were causing the shortages. Portugal, Poland, Romania, Belgium, Slovakia and Spain, in turn, have rules in place that likely make it impossible to export the drug, Affordable Medicines said. It also urged "all relevant actors" not to export the drugs.

Persons: George Frey REFILE, Spiegel, Lilly, Karl Broich, Eli Lilly's, tirzepatide, BfArM's Broich, Broich, PHAGRO, Germany's BfArM, Ludwig Burger, Miranda Murray, Patricia Weiss, Matthias Williams, Sharon Singleton Organizations: Novo Nordisk, Pharmacy, REUTERS, BfArM, EU, Novo Nordisk's, Spiegel, European Union, Medicines, Thomson Locations: Provo , Utah, U.S, FRANKFURT, United States, Europe, Britain, Belgium, Germany, Norway, Denmark, Medicines Europe, Austria, France, Greece, Czech Republic, Portugal, Poland, Romania, Slovakia, Spain, Frankfurt, Berlin

Search resuls for: "George Fre"

25 mentions found